Livzon Group disclosed the investor relations activity record sheet announcement that the company's new crown vaccine V-01 is a recombinant protein vaccine. Research and development of a mutant vaccine for Omicron has been carried out. Livzon's COVID-19 vaccine V-01 has been undergoing Phase III clinical trials in many overseas countries, and will also strive for opportunities to be sold overseas in the future. Although the domestic COVID-19 vaccination rate is already very high, and some provinces have successively launched the vaccination of reinforcing needles, we also expect V-01 to be listed in China as soon as possible as a booster needle.
The chairman of the company is Zhu Baoguo. Mr. Zhu Baoguo: Born in 1962, bachelor degree, was the director of Henan Xinxiang Waterborne Resin Research Institute, vice chairman and general manager of Henan Feilong Fine Chemical Products Co., Ltd., since 1992, he has served as the general manager and vice chairman of the company, and is currently the chairman of the company and the chairman of Lizhu Pharmaceutical Group Co., Ltd.
This article is compiled by the Securities Star Data Center based on publicly available data and does not constitute investment opinions or suggestions, if you have any questions, please contact us.
![[A prescription that can prevent both "fu" and "Ca", after reading the knowledge] "a glass of wine, a meal" is not a trivial, "corruption on the tip of the tongue", illegal banquets and drinking questions[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)